Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Assets Average (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Assets Average for 10 consecutive years, with $883.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 25.25% to $883.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $883.7 million, a 25.25% decrease, with the full-year FY2025 number at $1.0 billion, down 18.41% from a year prior.
  • Assets Average was $883.7 million for Q4 2025 at Intellia Therapeutics, down from $912.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.5 billion in Q1 2023 to a low of $694.6 million in Q2 2021.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 131.69% in 2021, then fell 25.25% in 2025.
  • Intellia Therapeutics' Assets Average stood at $1.3 billion in 2021, then dropped by 0.95% to $1.3 billion in 2022, then fell by 2.31% to $1.3 billion in 2023, then dropped by 7.07% to $1.2 billion in 2024, then dropped by 25.25% to $883.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Assets Average are $883.7 million (Q4 2025), $912.1 million (Q3 2025), and $942.5 million (Q2 2025).